New hope for older leukemia patients ineligible for harsh chemo
NCT ID NCT03513484
Summary
This study is testing the safety and best dose of an experimental drug, nintedanib, when combined with an approved drug, azacitidine. It is for older adults with a specific type of acute myeloid leukemia who are not candidates for or choose to avoid intensive chemotherapy. The main goal is to see if the combination is safe and tolerable while also checking if it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.